SUCCESSFUL PROGRESS REPORTED IN HAP ANIMAL STUDIES

MIV Therapeutics (MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies, has announced that its Hydroxyapatite (HAp) stent coating has demonstrated excellent performance and biocompatibility in key areas assessed at the three-month follow-up stage of an ongoing study in which HAp-coated stents were implanted in pig cardiovascular arteries. The results of the study, conducted at The Methodist Hospital Research Institute in cooperation with Texas Heart Institute, pave the way for upcoming human clinical trials of HAp coatings for stents.

PharmaLive (http://www.medadnews.com/News/Index.cfm?articleid=250894)